Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome
Apr 25, 2017 | News
Recent Posts
- Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome
- Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome
- Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome